Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma. This study is also intended to estimate how well your disease responds to this treatment.
Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin
DRUG: SGN-40|DRUG: rituximab|DRUG: gemcitabine
Determine the safety and adverse-event profile for combination therapy of SGN-40 with gemcitabine and rituximab., 10 months from registration of last patient
Estimate progression free survival, clinical response rates to treatment, and overall survival to determine efficacy., Follow-up every 6 weeks after end of treatment.
The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma. This study is also intended to estimate how well your disease responds to this treatment.